Amica Mutual Insurance Co. Sells 2,007 Shares of Lam Research Co. (NASDAQ:LRCX)

Amica Mutual Insurance Co. lowered its position in shares of Lam Research Co. (NASDAQ:LRCX) by 21.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,413 shares of the semiconductor company’s stock after selling 2,007 shares during the period. Amica Mutual Insurance Co.’s holdings in Lam Research were worth $5,806,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Orion Capital Management LLC purchased a new position in shares of Lam Research during the third quarter worth about $25,000. BluePath Capital Management LLC bought a new position in shares of Lam Research in the 3rd quarter worth $28,000. OFI Invest Asset Management purchased a new stake in shares of Lam Research during the 3rd quarter valued at $30,000. Asset Dedication LLC lifted its holdings in shares of Lam Research by 56.7% during the 3rd quarter. Asset Dedication LLC now owns 47 shares of the semiconductor company’s stock worth $30,000 after acquiring an additional 17 shares during the last quarter. Finally, Valued Wealth Advisors LLC bought a new stake in shares of Lam Research during the 4th quarter worth $30,000. Institutional investors own 84.61% of the company’s stock.

Lam Research Stock Up 0.4 %

LRCX stock traded up $3.44 during midday trading on Monday, hitting $928.81. The stock had a trading volume of 902,186 shares, compared to its average volume of 1,073,179. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.82 and a quick ratio of 1.84. The firm has a market cap of $121.77 billion, a price-to-earnings ratio of 34.16, a price-to-earnings-growth ratio of 2.88 and a beta of 1.51. The business has a 50-day moving average of $943.72 and a two-hundred day moving average of $813.44. Lam Research Co. has a 52-week low of $507.19 and a 52-week high of $1,007.39.

Lam Research (NASDAQ:LRCX) last issued its quarterly earnings results on Wednesday, April 24th. The semiconductor company reported $7.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.26 by $0.53. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.72 billion. Lam Research had a net margin of 25.35% and a return on equity of 45.96%. Lam Research’s revenue was down 2.0% on a year-over-year basis. During the same period last year, the company posted $6.99 EPS. As a group, equities research analysts forecast that Lam Research Co. will post 29.54 earnings per share for the current fiscal year.

Lam Research Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 3rd. Investors of record on Wednesday, March 13th were paid a $2.00 dividend. The ex-dividend date was Tuesday, March 12th. This represents a $8.00 annualized dividend and a dividend yield of 0.86%. Lam Research’s payout ratio is currently 29.42%.

Analyst Upgrades and Downgrades

LRCX has been the subject of several research analyst reports. Evercore ISI started coverage on Lam Research in a research note on Tuesday, April 16th. They set an “outperform” rating and a $1,200.00 price target for the company. The Goldman Sachs Group upped their target price on Lam Research from $700.00 to $912.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Barclays lifted their price target on shares of Lam Research from $825.00 to $865.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group upped their price objective on shares of Lam Research from $1,130.00 to $1,150.00 and gave the company a “buy” rating in a research note on Thursday. Finally, StockNews.com raised shares of Lam Research from a “hold” rating to a “buy” rating in a research note on Friday. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Lam Research presently has an average rating of “Moderate Buy” and a consensus target price of $950.85.

Insider Activity at Lam Research

In other news, SVP Seshasayee Varadarajan sold 5,500 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $922.41, for a total value of $5,073,255.00. Following the sale, the senior vice president now directly owns 22,095 shares of the company’s stock, valued at $20,380,648.95. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Lam Research news, Director Abhijit Y. Talwalkar sold 882 shares of Lam Research stock in a transaction on Monday, April 1st. The stock was sold at an average price of $972.03, for a total value of $857,330.46. Following the completion of the sale, the director now owns 10,541 shares of the company’s stock, valued at approximately $10,246,168.23. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Seshasayee Varadarajan sold 5,500 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $922.41, for a total value of $5,073,255.00. Following the transaction, the senior vice president now directly owns 22,095 shares in the company, valued at $20,380,648.95. The disclosure for this sale can be found here. Insiders sold a total of 7,029 shares of company stock valued at $6,559,489 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.